{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,20]],"date-time":"2026-02-20T02:07:48Z","timestamp":1771553268290,"version":"3.50.1"},"reference-count":47,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,8,5]],"date-time":"2022-08-05T00:00:00Z","timestamp":1659657600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>Patient populations, including those with hematological malignancies, have different responses to COVID-19 vaccines. This study aimed to quantitatively analyze the efficacy and safety of COVID-19 mRNA vaccines in patients with hematological malignancies. Studies reporting on the efficacy and safety of COVID-19 mRNA vaccines in cohorts with hematological malignancies compared to healthy controls were systematically searched in four databases. Meta-analysis and subgroup analyses were performed to generate quantitative synthesis. Fifteen studies with 2,055 cohorts with hematological malignancies and 1,105 healthy subjects as control were included. After two doses of COVID-19 vaccination, only 60% of cohorts with hematological malignancies were seroconverted compared to healthy controls (RR 0.60; 95%CI 0.50\u20130.71). A single dose of the vaccine resulted in a significantly lower seroconversion rate (RR 0.30; 95%CI 0.16\u20130.54). Non-Hodgkin lymphoma cohorts had the lowest rate of seroconversion (RR 0.5; 95%CI 0.35\u20130.71) and those who received active treatments had lower immunological responses (RR 0.59; 95%CI 0.46\u20130.75). Antibody titers were lower in cohorts with hematological malignancies without any differences in adverse effects in both groups. In conclusion, cohorts with hematological malignancies showed a lower seroconversion rate and antibody titers after receiving COVID-19 mRNA vaccines. The type of malignancy and the status of treatment had a significant impact on the response to vaccination. The vaccines were shown to be safe for both patients with hematological malignancies and healthy controls. Booster doses and stricter health protocols might be beneficial for patient populations.<\/jats:p>","DOI":"10.3389\/fonc.2022.951215","type":"journal-article","created":{"date-parts":[[2022,8,5]],"date-time":"2022-08-05T05:20:08Z","timestamp":1659676808000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":19,"title":["Efficacy and safety profile of COVID-19 mRNA vaccine in patients with hematological malignancies: Systematic review and meta-analysis"],"prefix":"10.3389","volume":"12","author":[{"given":"Ikhwan","family":"Rinaldi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Samuel","family":"Pratama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lowilius","family":"Wiyono","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeremy Rafael","family":"Tandaju","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Indy Larasati","family":"Wardhana","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kevin","family":"Winston","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2022,8,5]]},"reference":[{"key":"B1","unstructured":"WHO coronavirus (COVID-19) dashboard with vaccination data"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1101\/2020.06.10.20127589","article-title":"Effect of social distancing on COVID-19 incidence and mortality in the US","author":"VoPham","year":"2020","journal-title":"medRxiv"},{"key":"B3","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1007\/s10389-020-01321-z","article-title":"COVID-19 and social distancing","volume":"30","author":"Qian","year":"2022","journal-title":"Z Fur Gesundheitswissenschaften."},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1038\/s41562-021-01122-8","article-title":"A global database of COVID-19 vaccinations","volume":"5","author":"Mathieu","year":"2021","journal-title":"Nat Hum Behav"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0260733","article-title":"Vaccines to prevent COVID-19: A living systematic review with trial sequential analysis and network meta-analysis of randomized clinical trials","volume":"17","author":"Korang","year":"2022","journal-title":"PloS One"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2118691","article-title":"Protection against SARS-CoV-2 after covid-19 vaccination and previous infection","volume":"386","author":"Hall","year":"2022","journal-title":"N Engl J Med"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2021-068632","article-title":"Efficacy of covid-19 vaccines in immunocompromised patients: systematic review and meta-analysis","volume":"376","author":"Lee","year":"2022","journal-title":"BMJ."},{"key":"B8","doi-asserted-by":"publisher","first-page":"350","DOI":"10.3390\/vaccines10030350","article-title":"Efficacy and effectiveness of SARS-CoV-2 vaccines: A systematic review and meta-analysis","volume":"10","author":"Ghazy","year":"2022","journal-title":"Vaccines"},{"key":"B9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41541-021-00336-1","article-title":"Comparative systematic review and meta-analysis of reactogenicity, immunogenicity and efficacy of vaccines against SARS-CoV-2","volume":"6","author":"McDonald","year":"2021","journal-title":"NPJ Vaccines"},{"key":"B10","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1186\/s13045-022-01233-3","article-title":"Serologic response following SARS-COV2 vaccination in patients with cancer: a systematic review and meta-analysis","volume":"15","author":"Sakuraba","year":"2022","journal-title":"J Hematol Oncol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2021006333","article-title":"Immunogenicity of COVID-19 vaccines in patients with hematologic malignancies: a systematic review and meta-analysis","volume":"6","author":"Teh","year":"2022","journal-title":"Blood Adv"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1101\/2021.04.06.21254949","article-title":"Suboptimal response to COVID-19 mRNA vaccines in hematologic malignancies patients","author":"Agha","year":"2021","journal-title":"medRxiv."},{"key":"B13","doi-asserted-by":"publisher","first-page":"22777","DOI":"10.1038\/s41598-021-02321-z","article-title":"Comparing the clinical efficacy of COVID-19 vaccines: a systematic review and network meta-analysis","volume":"11","author":"Rotshild","year":"2021","journal-title":"Sci Rep"},{"key":"B14","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1186\/s40001-022-00648-5","article-title":"Immunogenicity of COVID-19 mRNA vaccines in immunocompromised patients: a systematic review and meta-analysis","volume":"27","author":"Mehrabi Nejad","year":"2022","journal-title":"Eur J Med Res"},{"key":"B15","doi-asserted-by":"publisher","first-page":"1048","DOI":"10.3390\/vaccines9091048","article-title":"Covid-19 vaccines in cancer patients. seropositivity and safety. systematic review and meta-analysis","volume":"9","author":"Cavanna","year":"2021","journal-title":"Vaccines."},{"key":"B16","doi-asserted-by":"publisher","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ."},{"key":"B17","doi-asserted-by":"publisher","first-page":"358:4008","DOI":"10.1136\/bmj.j4008","article-title":"AMSTAR 2: a critical appraisal tool for systematic reviews that include randomised or non-randomised studies of healthcare interventions, or both","author":"Shea","year":"2017","journal-title":"BMJ."},{"key":"B18","unstructured":"Checklist for cohort studies2017"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ."},{"key":"B20","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1186\/s12891-019-2619-8","article-title":"Preoperative opioid use is associated with worse patient outcomes after total joint arthroplasty: a systematic review and meta-analysis","volume":"20","author":"Goplen","year":"2019","journal-title":"BMC Musculoskelet Disord"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1111\/joor.12633","article-title":"Association between psychotropic medications and presence of sleep bruxism: A systematic review","volume":"45","author":"Melo","year":"2018","journal-title":"J Oral Rehabil."},{"key":"B22","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1002\/jrsm.1230","article-title":"Basics of meta-analysis: I 2 is not an absolute measure of heterogeneity","volume":"8","author":"Borenstein","year":"2017","journal-title":"Res Synth Methods"},{"key":"B23","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1038\/s41408-021-00528-x","article-title":"Antibody responses after first and second covid-19 vaccination in patients with chronic lymphocytic leukaemia","volume":"11","author":"Parry","year":"2021","journal-title":"Blood Cancer J"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.26284","article-title":"BNT162b2 COVID-19 vaccine is significantly less effective in patients with hematologic malignancies","volume":"96","author":"Tzarfati","year":"2021","journal-title":"Am J Hematol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.18001","article-title":"Durable humoral responses after the second anti-SARS-CoV-2 vaccine dose in chronic myeloid leukaemia patients on tyrosine kinase inhibitors","volume":"197","author":"Claudiani","year":"2022","journal-title":"Br J Haematol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2021005094","article-title":"Efficacy of the BNT162b2 mRNA COVID-19 vaccine in patients with b-cell non-Hodgkin lymphoma","volume":"5","author":"Perry","year":"2021","journal-title":"Blood Adv"},{"key":"B27","doi-asserted-by":"publisher","first-page":"3165","DOI":"10.1182\/blood.2021011568","article-title":"Efficacy of the BNT162b2 mRNA COVID-19 vaccine in patients with chronic lymphocytic leukemia","volume":"137","author":"Herishanu","year":"2021","journal-title":"Blood."},{"key":"B28","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1186\/s13045-021-01090-6","article-title":"Fifth-week immunogenicity and safety of anti-SARS-CoV-2 BNT162b2 vaccine in patients with multiple myeloma and myeloproliferative malignancies on active treatment: preliminary data from a single institution","volume":"14","author":"Pimpinelli","year":"2021","journal-title":"J Hematol Oncol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.17608","article-title":"Humoral response rate and predictors of response to BNT162b2 mRNA COVID19 vaccine in patients with multiple myeloma","volume":"195","author":"Avivi","year":"2021","journal-title":"Br J Haematol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2021005444","article-title":"Poor neutralizing antibody responses in 106 patients with WM after vaccination against SARS-CoV-2: A prospective study","volume":"5","author":"Gavriatopoulou","year":"2021","journal-title":"Blood Adv"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-021-01354-7","article-title":"Response to mRNA vaccination for COVID-19 among patients with multiple myeloma","volume":"35","author":"Stampfer","year":"2021","journal-title":"Leukemia."},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2021.103705","article-title":"Safety and efficacy of the mRNA BNT162b2 vaccine against SARS-CoV-2 in five groups of immunocompromised patients and healthy controls in a prospective open-label clinical trial","volume":"74","author":"Bergman","year":"2021","journal-title":"EBioMedicine."},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(21)00213-8","article-title":"Safety and immunogenicity of one versus two doses of the COVID-19 vaccine BNT162b2 for patients with cancer: interim analysis of a prospective observational study","volume":"22","author":"Monin","year":"2021","journal-title":"Lancet Oncol"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-021-00534-z","article-title":"Weak immunogenicity of SARS-CoV-2 vaccine in patients with hematologic malignancies","volume":"11","author":"Malard","year":"2021","journal-title":"Blood Cancer J"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1016\/j.exphem.2021.12.396","article-title":"Anti-CD20 monoclonal antibodies inhibit seropositive response to covid-19 vaccination in non-Hodgkin lymphoma patients within 6 months after treatment","volume":"107","author":"Tvito","year":"2022","journal-title":"Exp Hematol"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.17877","article-title":"T-Cell immune response after mRNA SARS-CoV-2 vaccines is frequently detected also in the absence of seroconversion in patients with lymphoid malignancies","volume":"196","author":"Marasco","year":"2022","journal-title":"Br J Haematol"},{"key":"B37","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1055\/s-0040-1712187","article-title":"Epidemiology of COVID-19","volume":"11","author":"Chowdhury","year":"2020","journal-title":"J Dig Endosc."},{"key":"B38","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1001\/jamaoncol.2021.5148","article-title":"Evaluation of COVID-19 mortality and adverse outcomes in US patients with or without cancer","volume":"8","author":"Chavez-Macgregor","year":"2022","journal-title":"JAMA Oncol"},{"key":"B39","unstructured":"COVID-19 vaccines2022"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1097\/01.md.0000232560.22098.4e","article-title":"Respiratory viral infections in adults with hematologic malignancies and human stem cell transplantation recipients: a retrospective study at a major cancer center","volume":"85","author":"Chemaly","year":"2006","journal-title":"Med (Baltimore)."},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2020.6775","article-title":"Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the new York city area","volume":"323","author":"Richardson","year":"2020","journal-title":"JAMA."},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2020.2648","article-title":"Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: Summary of a report of 72 314 cases from the Chinese center for disease control and prevention","volume":"323","author":"Wu","year":"2020","journal-title":"JAMA."},{"key":"B43","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41408-021-00546-9","article-title":"Production and persistence of specific antibodies in COVID-19 patients with hematologic malignancies: role of rituximab","volume":"11","author":"Cattaneo","year":"2021","journal-title":"Blood Cancer J"},{"key":"B44","doi-asserted-by":"publisher","first-page":"3940","DOI":"10.3390\/curroncol29060315","article-title":"A Canadian perspective: Monoclonal antibodies for pre- and post-exposure protection from COVID-19 in vulnerable patients with hematological malignancies","volume":"29","author":"Owen","year":"2022","journal-title":"Curr Oncol"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2116620","article-title":"Intramuscular AZD7442 (Tixagevimab\u2013cilgavimab) for prevention of covid-19","volume":"386","author":"Levin","year":"2022","journal-title":"N Engl J Med"},{"key":"B46","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1038\/s41571-022-00610-8","article-title":"COVID-19 vaccines in patients with cancer: immunogenicity, efficacy and safety","volume":"19","author":"Fendler","year":"2022","journal-title":"Nat Rev Clin Oncol"},{"key":"B47","doi-asserted-by":"publisher","first-page":"563","DOI":"10.3390\/cells9030563","article-title":"Recent progress of stem cell therapy in cancer treatment: Molecular mechanisms and potential applications","volume":"9","author":"Chu","year":"2020","journal-title":"Cells."}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2022.951215\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,5]],"date-time":"2022-08-05T05:20:14Z","timestamp":1659676814000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2022.951215\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,5]]},"references-count":47,"alternative-id":["10.3389\/fonc.2022.951215"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2022.951215","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,5]]},"article-number":"951215"}}